MedTrace Logo

Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients

NCT01028794 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-07-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether autologous bone marrow mononuclear cells transplantation after stroke is safe and/or effective to improve neurological outcome.

Conditions

Interventions

BIOLOGICAL

autologous bone marrow mononuclear cells

intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)

BIOLOGICAL

autologous bone marrow mononuclear cells

intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)

Sponsors & Collaborators

  • Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan

    collaborator OTHER

  • National Cerebral and Cardiovascular Center, Japan

    lead OTHER

Principal Investigators

  • Akihiko Taguchi, MD.PhD · Department of Cerebrovascular Disease, National Cardiovascular Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01028794 on ClinicalTrials.gov